Enjoy these great presentations on the future of non-invasive neurotech, delivered at the 2014 SharpBrains Virtual Summit and featuring:
- Dr. Bruce Cuthbert, Director of Adult Translational Research and Treatment Development at the NIMH
- Charles Fisher, President of Fisher Wallace Laboratories
- Chair: James Cavuoto, Editor and Publisher at Neurotech Reports
We are proud to share that Dr. Thomas Insel, Director of the National Institute of Mental Health and neurotechnology visionary, will open the 2014 SharpBrains Virtual Summit on Tuesday, October 28th.
Prior to this appointment at NIMH, Dr. Insel was Professor of Psychiatry at Emory University, where he was founding director of the Center for Behavioral Neuroscience. He has published over 250 scientific articles and four books, served on numerous academic, scientific, and professional committees and boards, and is a recipient of several awards, including the Outstanding Service Award from the U.S. Public Health Service. Dr. Insel graduated from the combined B.A.-M.D. program at Boston University, did his internship at Berkshire Medical Center, Massachusetts, and his residency at the Langley Porter Neuropsychiatric Institute at the University of California, San Francisco.
–> Explore the Agenda at 2014 SharpBrains Virtual Summit, and consider joining us October 28-30th!
By: Alvaro Fernandez
Blazing Trails in Brain Science (The New York Times):
“The pendulum has swung so far toward drug therapy in recent years that it is hard to recapture how disruptive those 1980 studies were. Dr. Insel’s work and that of many others, testing the effect of new medications, would turn the field away from long-term talking cures and increasingly toward medication and short-term behavior therapies rooted in the same kind of randomized, controlled trials conducted in other fields of medicine…Yet the overall impact of this drug revolution on public health has been mixed…”
To Learn More:
Transforming Diagnosis (article by Thomas Insel, Director of the NIMH): “In a few weeks, the American Psychiatric Association will release its new edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)…While DSM has been described as a “Bible” for the field, it is, at best, a dictionary, creating Read the rest of this entry »
By: Alvaro Fernandez
We’re having a good conversation among SharpBrains Summit participants, prompted by the blog post Lifelong brain wellness and performance–not medical disease–drives growing demand for digital brain health solutions. In what is a beautiful example of the need to see both the forest and the trees Read the rest of this entry »
Below you can find the full transcript of our engaging Q&A session today, Friday March 16th, on brain sustainability, retooling brain health, and applied neuroplasticity, with Alvaro Fernandez, SharpBrains’ Co-Founder who’s just been named a Young Global Leader by the World Economic Forum. You can learn more about the topic by reading this 2011 SharpBrains Summit Meeting Report and this Infographic.
Great, we are ready to start! Read the rest of this entry »
By: Dr. Evian Gordon
(Editor’s Note: this is Part 2 of the new 3-part series written by Dr. Evian Gordon drawing from his participation at the Personalized Medicine World Congress on January, 23, 2012 at Stanford University.)
Most Personalized Medicine research in Psychiatry using molecular measures alone have failed to replicate. Whilst disappointing, this is not surprising, since 80% of human 25,000 genes have some effect on the brain.
There are therefore growing efforts expanding Genomic Biomarkers in Psychiatry to Neuroimaging (all Brain-based biological and cognitive measures). Some approaches target Read the rest of this entry »